The Institute for Clinical and Economic Review has weighed in on what is expected to be the most expensive drug yet to reach the US market – Spark Therapeutics Inc.'s gene therapy Luxturna (vortigene neparvovic), a one-time treatment for an inherited form of blindness that could set the price bar for future gene therapies. ICER's draft conclusions could give payers leverage as they negotiate reimbursement for what is expected to be an ultra-pricey therapy for an ultra-orphan indication.
In a draft evidence report released Nov. 14 on Luxturna for biallelic RPE65-mediated retinal disease, ICER concluded that a $1m price for Luxturna would not likely be cost-effective based on traditional thresholds
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?